Antibodies against PF4/heparin complexes generate an activation of platelets with release of procoagulant microparticles and increased generation of thrombin leading to thrombocytopenia based on platelet consumption within thrombotic formations and life-threatening arterial and venous thromboembolic events (Dasararaju et al. 2013; Linkins et al. 2012; Greinacher et al. 2010). This evidence concerns the gene PF4 and Thrombocytopenia.